Main

processing priority

4

site type

0 (generic, awaiting analysis)

review version

11

html import

20 (imported)

Events

first seen date

2024-02-25 01:16:38

expired found date

-

created at

2024-06-29 03:31:12

updated at

2024-06-30 09:12:02

Domain name statistics

length

11

crc

49041

tld

2211

nm parts

0

nm random digits

0

nm rare letters

0

Connections

is subdomain of id

-

previous id

0

replaced with id

0

related id

-

dns primary id

120891333

dns alternative id

0

lifecycle status

0 (unclassified, or currently active)

Subdomains and pages

deleted subdomains

0

page imported products

0

page imported random

0

page imported parking

0

Error counters

count skipped due to recent timeouts on the same server IP

0

count content received but rejected due to 11-799

0

count dns errors

0

count cert errors

0

count timeouts

0

count http 429

0

count http 404

0

count http 403

0

count http 5xx

0

next operation date

-

Server

server bits

server ip

-

Mainpage statistics

mp import status

20

mp rejected date

-

mp saved date

-

mp size orig

73373

mp size raw text

6505

mp inner links count

0

mp inner links status

1 (no links)

Open Graph

title

description

image

site name

author

updated

2026-01-03 02:54:22

raw text

 荣昌生物制药(烟台)股份有限公司_荣昌生物 荣昌生物官方网站首页 Home About Us Our Company Our Vision Our Board of Directors Our Management Team Scientific Advisory Board Products Telitacicept Disitamab Vedotin Product Pipeline Production and Manufacturing Quality Assurance R & D Renovation Capabilities Technology Platform Talent Team Investors Information Disclosure Corporate Governance IR Contacts News Company News Press Release Join Us Recruitment Working at RemeGen Contact Us Company Address Clinical Trial Products Consulting Human Resource Adverse drug reaction reports Lang 中文简体 中文繁体 Products Telitacicept Telitacicept is the world’s first and first-in-class recombinant B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) dual-target novel fusion protein product for injection independently developed by RemeGen. A total of eight of its indications in the field of autoimmune disea...

Text analysis

redirect type

0 (-)

block type

0 (no issues)

detected language

1 (English)

category id

221

index version

2025123101

spam phrases

0

Text statistics

text nonlatin

48

text cyrillic

0

text characters

5054

text words

912

text unique words

369

text lines

141

text sentences

14

text paragraphs

8

text words per sentence

65

text matched phrases

2

text matched dictionaries

4

RSS

rss path

rss status

1 (priority 1 already searched, no matches found)

rss found date

-

rss size orig

0

rss items

0

rss spam phrases

0

rss detected language

0 (awaiting analysis)

inbefore feed id

-

inbefore status

0 (new)

Sitemap

sitemap path

sitemap status

1 (priority 1 already searched, no matches found)

sitemap review version

2

sitemap urls count

0

sitemap urls adult

0

sitemap filtered products

0

sitemap filtered videos

0

sitemap found date

-

sitemap process date

2024-06-29 03:31:12

sitemap first import date

-

sitemap last import date

-